Rein TherapeuticsRNTX.OValuation Analysis

As of Oct 16, 2026, Rein Therapeutics (RNTX.O) trades at a negative P/E (-1.02x, due to a recent net loss), P/B of 0.92x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 32nd percentile over the trailing 10Y window (vs. 13th percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 20th percentile within its industry and the 26th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Rein Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.